An Auckland woman who is self-funding treatment for her rare, aggressive breast cancer is fed up after years of asking the government to fund a “life-saving” medicine for more patients.
Catherine Cook, 54, was diagnosed with triple negative breast cancer (TNBC) in November 2024 after her yearly mammogram.
Cook sold her business to pay for Keytruda (also known as pembrolizumab), the only targeted treatment to fight TNBC, given to patients alongside chemotherapy.
Around 10 to 15 per cent of breast cancer diagnoses are triple negative, and it is the most challenging type of breast cancer to treat – particularly at the advanced stages, according to Breast Cancer NZ.
But despite Keytruda being recommended by Medsafe for both early and advanced stage of TNBC over two years ago, it had only been funded for advanced patients – not for patients like Cook with early-stage TNBC.
All up, Cook said she expected to pay about $100,000 for Keytruda, with one cycle every three weeks costing her $3000.
RNZ
Face of the Day
Despite Keytruda being recommended by Medsafe for both early and advanced stage of TNBC over two years ago, it has only been funded for advanced patients – not for patients like Cook with early-stage TNBC.
Latest
Looking for Climate Activists, but Found Communists
We came to New York prepared to debate climate radicals in the streets. For most of the week, we couldn’t find them. So eventually we found some communists instead. And we brought the climate debate to them.
But It Said ‘Top Secret’ and Everything!
Who thought sending stealth fighter parts through the mail was a good idea?